ALK and non-small cell lung carcinoma: Crizotinib was negatively associated with ELAVL1, CBLL1, HNRNPC and RBM15B, which proved that crizotinib was sensitive to ELAVL1, CBLL1, HNRNPC and RBM15B.With the fact that crizotinib is a kinase inhibitor targeting c-MET/ALK/ROS1, which is the fisrt-line chemical treatment to NSCLC with ALK mutations, most NSCLCs are resistant to crizotinib treatment without considering the overexpression of c-MET in about 35–72% NSCLC.